Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...
South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab ... launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback